The apolipoprotein E ε4 allele plays pathological roles in AD through high protein expression and interaction with butyrylcholinesterase

Neurobiology of Aging

Volumn 32, Issue 7, 2011, Pages 1236-1248

  Darreh Shori, Taher ^a   Modiri, Negar ^a   Blennow, Kaj ^c   Baza, Souad ^a   Kamil, Chelenk ^a   Ahmed, Hiba ^a   Andreasen, Niels ^b   Nordberg, Agneta ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer's disease; Apolipoprotein E; Beta amyloid; Butyrylcholinesterase; Fibrillization; Proinflammatory cytokine (IL 1 ); Risk factors

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; ISOPROTEIN; TAU PROTEIN;

AGED; AGING; ALLELE; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENETIC ASSOCIATION; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; RISK FACTOR; SEX DIFFERENCE;

AGED; ALLELES; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; APOLIPOPROTEIN E4; BIOLOGICAL MARKERS; BRAIN; BUTYRYLCHOLINESTERASE; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MALE; PROTEIN INTERACTION MAPPING; RISK FACTORS;

EID: 79952231145     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2009.07.015     Document Type: Article

References (63)

1. Appleyard M.E., Smith A.D., Berman P., Wilcock G.K., Esiri M.M., Neary D., Bowen D.M. Cholinesterase activities in cerebrospinal fluid of patients with senile dementia of Alzheimer type. Brain 1987, 110:1309-1322.
2. Arendt T., Bruckner M.K., Lange M., Bigl V. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development-a study of molecular forms. Neurochem. Int. 1992, 21:381-396.
3. Beffert U., Stolt P.C., Herz J. Functions of lipoprotein receptors in neurons. J. Lipid. Res. 2004, 45:403-409.
4. Braak H., de Vos R.A., Jansen E.N., Bratzke H., Braak E. Neuropathological hallmarks of Alzheimer's and Parkinson's diseases. Prog. Brain Res. 1998, 117:267-285.
5. Darreh-Shori T., Almkvist O., Guan Z.Z., Garlind A., Strandberg B., Svensson A.L., Soreq H., Hellstrom-Lindahl E., Nordberg A. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology 2002, 59:563-572.
6. Darreh-Shori T., Brimijoin S., Kadir A., Almkvist O., Nordberg A. Differential CSF butyrylcholinesterase levels in Alzheimer's disease patients with the ApoE epsilon4 allele, in relation to cognitive function and cerebral glucose metabolism. Neurobiol. Dis. 2006, 24:326-333.
7. Darreh-Shori T., Kadir A., Almkvist O., Grut M., Wall A., Blomquist G., Eriksson B., Langstrom B., Nordberg A. Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine. Neurobiol. Aging 2008, 29:168-184.
8. Darreh-Shori T., Modiri N., Lahaut P., Nordberg A. Apolipoprotein E and butyrylcholinesterase synergistically promote amyloid-beta peptides oligomerization. ICAD 2009, Alzheimers Dement, Abstract P1-163.
9. Darreh-Shori T., Modiri N., Nordberg A. ApoE and amyloid beta deflate the cholinergic neurotransmission by boosting the activity and stability of cholinesterases in the brain. ICAD 2009, Alzheimers Dement, Abstract P2-151.
10. Davies P., Maloney A.J. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976, 2:1403.
11. de-Andrade F.M., Larrandaburu M., Callegari-Jacques S.M., Gastaldo G., Hutz M.H. Association of apolipoprotein E polymorphism with plasma lipids and Alzheimer's disease in a Southern Brazilian population. Braz. J. Med. Biol. Res. 2000, 33:529-537.
12. Diamant S., Podoly E., Friedler A., Ligumsky H., Livnah O., Soreq H. Butyrylcholinesterase attenuates amyloid fibril formation in vitro. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:8628-8633.
13. Farrer L.A., Cupples L.A., Haines J.L., Hyman B., Kukull W.A., Mayeux R., Myers R.H., Pericak-Vance M.A., Risch N., van Duijn C.M. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997, 278:1349-1356.
14. Forsberg A., Engler H., Almkvist O., Blomquist G., Hagman G., Wall A., Ringheim A., Langstrom B., Nordberg A. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol. Aging 2008, 29(10):1456-1465.
15. Fryer J.D., Demattos R.B., McCormick L.M., O'Dell M.A., Spinner M.L., Bales K.R., Paul S.M., Sullivan P.M., Parsadanian M., Bu G., Holtzman D.M. The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice. J. Biol. Chem. 2005, 280:25754-25759.
16. Giacobini E., Spiegel R., Enz A., Veroff A.E., Cutler N.R. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit. J. Neural. Transm. 2002, 109:1053-1065.
17. Gong J.S., Kobayashi M., Hayashi H., Zou K., Sawamura N., Fujita S.C., Yanagisawa K., Michikawa M. Apolipoprotein E (ApoE) isoform-dependent lipid release from astrocytes prepared from human ApoE3 and ApoE4 knock-in mice. J. Biol. Chem. 2002, 277:29919-29926.
18. Gronroos P., Raitakari O.T., Kahonen M., Hutri-Kahonen N., Marniemi J., Viikari J., Lehtimaki T. Influence of apolipoprotein E polymorphism on serum lipid and lipoprotein changes: a 21-year follow-up study from childhood to adulthood. The Cardiovascular Risk in Young Finns Study. Clin. Chem. Lab. Med. 2007, 45:592-598.
19. Guillozet A.L., Smiley J.F., Mash D.C., Mesulam M.M. Butyrylcholinesterase in the life cycle of amyloid plaques. Ann. Neurol. 1997, 42:909-918.
20. Hajjar I., Schumpert J., Hirth V., Wieland D., Eleazer G.P. The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J. Gerontol. A: Biol. Sci. Med. Sci. 2002, 57:M414-418.
21. Hayashi H., Campenot R.B., Vance D.E., Vance J.E. Apolipoprotein E-containing lipoproteins protect neurons from apoptosis via a signaling pathway involving low-density lipoprotein receptor-related protein-1. J. Neurosci. 2007, 27:1933-1941.
22. Herz J., Beffert U. Apolipoprotein E receptors: linking brain development and Alzheimer's disease. Nat. Rev. Neurosci. 2000, 1:51-58.
23. Inestrosa N.C., Alvarez A., Calderon F. Acetylcholinesterase is a senile plaque component that promotes assembly of amyloid beta-peptide into Alzheimer's filaments. Mol. Psychiatry 1996, 1:359-361.
24. Kadir A., Andreasen N., Almkvist O., Wall A., Forsberg A., Engler H., Hagman G., Larksater M., Winblad B., Zetterberg H., Blennow K., Langstrom B., Nordberg A. Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. Ann. Neurol. 2008, 63(5):621-631.
25. Kester M.I., Blankenstein M.A., Bouwman F.H., van Elk E.J., Scheltens P., van der Flier W.M. CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age. J. Alzheimers Dis. 2009, 16:601-607.
26. Ki C.S., Na D.L., Kim J.W., Kim H.J., Kim D.K., Yoon B.K. No association between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset Alzheimer's disease. Am. J. Med. Genet. 1999, 88:113-115.
27. Kivipelto M., Rovio S., Ngandu T., Kareholt I., Eskelinen M., Winblad B., Hachinski V., Cedazo-Minguez A., Soininen H., Tuomilehto J., Nissinen A. Apolipoprotein E epsilon4 magnifies lifestyle risks for dementia: a population based study. J. Cell. Mol. Med. 2008, 12(6B):2762-2771.
28. Kuhl D.E., Koeppe R.A., Snyder S.E., Minoshima S., Frey K.A., Kilbourn M.R. In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses. Ann. Neurol. 2006, 59(1):13-20.
29. Lane R., Feldman H.H., Meyer J., He Y., Ferris S.H., Nordberg A., Darreh-Shori T., Soininen H., Pirttila T., Farlow M.R., Sfikas N., Ballard C., Greig N.H. Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease. Pharmacogenet. Genomics 2008, 18:289-298.
30. Lee D.W., Liu H.C., Liu T.Y., Chi C.W., Hong C.J. No association between butyrylcholinesterase K-variant and Alzheimer disease in Chinese. Am. J. Med. Genet. 2000, 96:167-169.
31. Lehmann D.J., Johnston C., Smith A.D. Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease. Hum. Mol. Genet. 1997, 6:1933-1936.
32. Lehmann D.J., Nagy Z., Litchfield S., Borja M.C., Smith A.D. Association of butyrylcholinesterase K variant with cholinesterase-positive neuritic plaques in the temporal cortex in late-onset Alzheimer's disease. Hum. Genet. 2000, 106:447-452.
33. Liu Q., Zerbinatti C.V., Zhang J., Hoe H.S., Wang B., Cole S.L., Herz J., Muglia L., Bu G. Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron 2007, 56:66-78.
34. Mahley R.W., Rall S.C. Apolipoprotein E: far more than a lipid transport protein. Annu. Rev. Genomics Hum. Genet. 2000, 1:507-537.
35. Martins I.J., Hone E., Foster J.K., Sunram-Lea S.I., Gnjec A., Fuller S.J., Nolan D., Gandy S.E., Martins R.N. Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Mol. Psychiatry 2006, 11:721-736.
36. McIlroy S.P., Crawford V.L., Dynan K.B., McGleenon B.M., Vahidassr M.D., Lawson J.T., Passmore A.P. Butyrylcholinesterase K variant is genetically associated with late onset Alzheimer's disease in Northern Ireland. J. Med. Genet. 2000, 37:182-185.
37. McKeith I.G., O'Brien K.K., Morris C.M., Perry E.K. Butyrylcholinesterase and dementia with Lewy bodies: involvement in symptom progression and treatment response. Butyrylcholinesterase: Its Function and Inhibitors 2003, 149-162. Martin Dunitz, London. E. Giacobini (Ed.).
38. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
39. Mesulam M.M., Geula C. Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann. Neurol. 1994, 36:722-727.
40. Mesulam M.M., Guillozet A., Shaw P., Levey A., Duysen E.G., Lockridge O. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience 2002, 110:627-639.
41. Meyers C.A. Mood and cognitive disorders in cancer patients receiving cytokine therapy. Adv. Exp. Med. Biol. 1999, 461:75-81.
42. Michikawa M., Fan Q.W., Isobe I., Yanagisawa K. Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture. J. Neurochem. 2000, 74:1008-1016.
43. Nieminen T., Kahonen M., Viiri L.E., Gronroos P., Lehtimaki T. Pharmacogenetics of apolipoprotein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease. Pharmacogenomics 2008, 9:1475-1486.
44. Notkola I.L., Sulkava R., Pekkanen J., Erkinjuntti T., Ehnholm C., Kivinen P., Tuomilehto J., Nissinen A. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 1998, 17:14-20.
45. Perry E., McKeith I., Ballard C. Butyrylcholinesterase and progression of cognitive deficits in dementia with Lewy bodies. Neurology 2003, 60:1852-1853.
46. Perry E.K., Perry R.H., Blessed G., Tomlinson B.E. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol. Appl. Neurobiol. 1978, 4:273-277.
47. Podoly E., Bruck T., Diamant S., Melamed-Book N., Weiss A., Huang Y., Livnah O., Langermann S., Wilgus H., Soreq H. Human recombinant butyrylcholinesterase purified from the milk of transgenic goats interacts with beta-amyloid fibrils and suppresses their formation in vitro. Neurodegener. Dis. 2008, 5:232-236.
48. Poirier J. Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease. Neurobiol. Aging 2005, 26:355-361.
49. Qiu Z., Crutcher K.A., Hyman B.T., Rebeck G.W. ApoE isoforms affect neuronal N-methyl-d-aspartate calcium responses and toxicity via receptor-mediated processes. Neuroscience 2003, 122:291-303.
50. Rapp A., Gmeiner B., Huttinger M. Implication of apoE isoforms in cholesterol metabolism by primary rat hippocampal neurons and astrocytes. Biochimie 2006, 88:473-483.
51. Raygani A.V., Rahimi Z., Kharazi H., Tavilani H., Pourmotabbed T. Association between apolipoprotein E polymorphism and serum lipid and apolipoprotein levels with Alzheimer's disease. Neurosci. Lett. 2006, 408:68-72.
52. Raygani A.V., Zahrai M., Raygani A.V., Doosti M., Javadi E., Rezaei M., Pourmotabbed T. Association between apolipoprotein E polymorphism and Alzheimer disease in Tehran, Iran. Neurosci. Lett. 2005, 375:1-6.
53. Raygani A.V., Zahrai M., Soltanzadeh A., Doosti M., Javadi E., Pourmotabbed T. Analysis of association between butyrylcholinesterase K variant and apolipoprotein E genotypes in Alzheimer's disease. Neurosci. Lett. 2004, 371:142-146.
54. Rebeck G.W., Reiter J.S., Strickland D.K., Hyman B.T. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 1993, 11:575-580.
55. Sparks D.L., Kryscio R.J., Sabbagh M.N., Connor D.J., Sparks L.M., Liebsack C. Reduced risk of incident AD with elective statin use in a clinical trial cohort. Curr. Alzheimer Res. 2008, 5:416-421.
56. Strittmatter W.J., Saunders A.M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G.S., Roses A.D. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:1977-1981.
57. Strittmatter W.J., Weisgraber K.H., Huang D.Y., Dong L.M., Salvesen G.S., Pericak-Vance M., Schmechel D., Saunders A.M., Goldgaber D., Roses A.D. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:8098-8102.
58. Sweeney D., Martins R., LeVine H., Smith J.D., Gandy S. Similar promotion of Abeta1-42 fibrillogenesis by native apolipoprotein E epsilon3 and epsilon4 isoforms. J. Neuroinflammation 2004, 1:15.
59. Wang H., Yu M., Ochani M., Amella C.A., Tanovic M., Susarla S., Li J.H., Yang H., Ulloa L., Al-Abed Y., Czura C.J., Tracey K.J. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003, 421:384-388.
60. Wiebusch H., Poirier J., Sevigny P., Schappert K. Further evidence for a synergistic association between APOE epsilon4 and BCHE-K in confirmed Alzheimer's disease. Hum. Genet. 1999, 104:158-163.
61. Wood K.C., Fullerton M.D., El-Sohemy A., Bakovic M. Interactions between hepatic lipase and apolipoprotein E gene polymorphisms affect serum lipid profiles of healthy Canadian adults. Appl. Physiol. Nutr. Metab. 2008, 33:761-768.
62. Ye S., Huang Y., Mullendorff K., Dong L., Giedt G., Meng E.C., Cohen F.E., Kuntz I.D., Weisgraber K.H., Mahley R.W. Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:18700-18705.
63. Zhu S.G., Sheng J.G., Jones R.A., Brewer M.M., Zhou X.Q., Mrak R.E., Griffin W.S. Increased interleukin-1beta converting enzyme expression and activity in Alzheimer disease. J. Neuropathol. Exp. Neurol. 1999, 58:582-587.